Development of copper-catalyzed azide-alkyne cycloaddition for increased in vivo efficacy of interferon β-1b by site-specific PEGylation

Bioconjugate Chemistry

Volumn 23, Issue 10, 2012, Pages 2087-2097

  Nairn, Natalie W ^a   Shanebeck, Kurt D ^a   Wang, Aijun ^a   Graddis, Thomas J ^a,b   Vanbrunt, Michael Pete ^a   Thornton, Kenneth C ^a   Grabstein, Kenneth ^a  

^a Allozyne   (United States)

^b Altravax Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CATALYSIS; COPPER COMPOUNDS; GLYCOPROTEINS; HYDROCARBONS; RECOMBINANT PROTEINS; SULFUR COMPOUNDS; TUMORS;

BIOORTHOGONAL REACTIONS; CLICK CHEMISTRY; COMPLETE CONTROL; COPPER CATALYZED AZIDE ALKYNE CYCLOADDITION; IN-VIVO; NON NATURAL AMINO ACIDS; PEGYLATION; PROTEIN CONJUGATES; SITE-SPECIFIC; VIVO EFFICACIES;

REDOX REACTIONS;

ALKYNE; AZIDE; COPPER; COPPER SULFATE; DITHIOTHREITOL; INTERFERON BETA SERINE; PEGINTERFERON BETA1A;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CATALYSIS; CHEMICAL REACTION; CLICK CHEMISTRY; CONTROLLED STUDY; CYCLOADDITION; DRUG EFFICACY; HALF LIFE TIME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOPLASM; NONHUMAN; OXIDATION REDUCTION POTENTIAL; XENOGRAFT;

EID: 84867550766     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300295x     Document Type: Article

References (63)

1. Leader, B., Baca, Q. J., and Golan, D. E. (2008) Protein therapeutics: a summary and pharmacological classification Nature Rev. Drug Discovery 7, 21-39
2. Wang, Y. S., Youngster, S., Grace, M., Bausch, J., Bordens, R., and Wyss, D. F. (2002) Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications Adv. Drug Delivery Rev. 54, 547-570 (Pubitemid 34618512)
3. Seattle Genetics ADCETRIS prescribing information, (2011).
4. Sun, M. M., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G., Ihle, N. C., Senter, P. D., and Alley, S. C. (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides Bioconjugate Chem. 16, 1282-1290 (Pubitemid 41368132)
5. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., Meyer, D. L., and Francisco, J. A. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10, 7063-7070 (Pubitemid 39383058)
6. Kinstler, O. B., Brems, D. N., Lauren, S. L., Paige, A. G., Hamburger, J. B., and Treuheit, M. J. (1996) Characterization and stability of N-terminally PEGylated rhG-CSF Pharm. Res. 13, 996-1002 (Pubitemid 26258997)
7. Kinstler, O., Molineux, G., Treuheit, M., Ladd, D., and Gegg, C. (2002) Mono-N-terminal poly(ethylene glycol)-protein conjugates Adv. Drug Delivery Rev. 54, 477-485 (Pubitemid 34615544)
8. Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., Lu, Y., Meng, Y. G., Ng, C., Yang, J., Lee, C. C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., Flagella, K., Venook, R., Ross, S., Spencer, S. D., Lee Wong, W., Lowman, H. B., Vandlen, R., Sliwkowski, M. X., Scheller, R. H., Polakis, P., and Mallet, W. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nature Biotechnol. 26, 925-932
9. Alley, S. C., Okeley, N. M., and Senter, P. D. (2010) Antibody-drug conjugates: targeted drug delivery for cancer Curr. Opin. Chem. Biol. 14, 529-537
10. Bailon, P. and Won, C. Y. (2009) PEG-modified biopharmaceuticals Expert Opin. Drug Delivery 6, 1-16
11. McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francisco, J. A., and Carter, P. (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng., Des. Sel. 19, 299-307 (Pubitemid 43999640)
12. Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W. J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z. X., Modi, M. W., Farid, A., Berthold, W., and Graves, M. (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C Bioconjugate Chem. 12, 195-202 (Pubitemid 32235471)
13. Foser, S., Schacher, A., Weyer, K. A., Brugger, D., Dietel, E., Marti, S., and Schreitmuller, T. (2003) Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS) Protein Expression Purif. 30, 78-87 (Pubitemid 36815235)
14. Basu, A., Yang, K., Wang, M., Liu, S., Chintala, R., Palm, T., Zhao, H., Peng, P., Wu, D., Zhang, Z., Hua, J., Hsieh, M. C., Zhou, J., Petti, G., Li, X., Janjua, A., Mendez, M., Liu, J., Longley, C., Zhang, Z., Mehlig, M., Borowski, V., Viswanathan, M., and Filpula, D. (2006) Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation Bioconjugate Chem 17, 618-630 (Pubitemid 43794371)
15. Liu, C. C. and Schultz, P. G. (2010) Adding new chemistries to the genetic code Annu. Rev. Biochem. 79, 413-444
16. Wang, A., Nairn, N. W., Marelli, M., and Grabstein, K. (2012) Protein Engineering with Non-Natural Amino Acids. In Protein Engineering (Kaumaya, P., Ed.), InTech, New York.
17. Hendrickson, T. L., de Crecy-Lagard, V., and Schimmel, P. (2004) Incorporation of nonnatural amino acids into proteins Annu. Rev. Biochem. 73, 147-176 (Pubitemid 39050366)
18. Cho, H., Daniel, T., Buechler, Y. J., Litzinger, D. C., Maio, Z., Putnam, A. M., Kraynov, V. S., Sim, B. C., Bussell, S., Javahishvili, T., Kaphle, S., Viramontes, G., Ong, M., Chu, S., Becky, G. C., Lieu, R., Knudsen, N., Castiglioni, P., Norman, T. C., Axelrod, D. W., Hoffman, A. R., Schultz, P. G., DiMarchi, R. D., and Kimmel, B. E. (2011) Optimized clinical performance of growth hormone with an expanded genetic code Proc. Natl. Acad. Sci. U. S. A. 108, 9060-9065
19. Sletten, E. M. and Bertozzi, C. R. (2009) Bioorthogonal chemistry: fishing for selectivity in a sea of functionality Angew. Chem., Int. Ed. Engl. 48, 6974-6998
20. Link, A. J. and Tirrell, D. A. (2005) Reassignment of sense codons in vivo Methods 36, 291-298 (Pubitemid 41074960)
21. Gonzalez-Navajas, J. M., Lee, J., David, M., and Raz, E. (2012) Immunomodulatory functions of type I interferons Nature Rev. Immunol. 12, 125-135
22. Peters, M. (1996) Actions of cytokines on the immune response and viral interactions: an overview Hepatology 23, 909-916 (Pubitemid 26112009)
23. Sen, G. C. and Lengyel, P. (1992) The interferon system: a bird's eye view of its biochemistry J. Biol. Chem. 267, 5017-5020
24. Dhib-Jalbut, S. and Marks, S. (2010) Interferon-beta mechanisms of action in multiple sclerosis Neurology 74, S17-S24
25. Fishburn, C. S. (2008) The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics J. Pharm. Sci. 97, 4167-4183
26. Hu, X., Miller, L., Richman, S., Hitchman, S., Glick, G., Liu, S., Zhu, Y., Crossman, M., Nestorov, I., Gronke, R. S., Baker, D. P., Rogge, M., Subramanyam, M., and Davar, G. (2012) A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology J. Clin. Pharmacol. 52, 798-808
27. Baker, D. P., Pepinsky, R. B., Brickelmaier, M., Gronke, R. S., Hu, X., Olivier, K., Lerner, M., Miller, L., Crossman, M., Nestorov, I., Subramanyam, M., Hitchman, S., Glick, G., Richman, S., Liu, S., Zhu, Y., Panzara, M. A., and Davar, G. (2010) PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis J. Interferon Cytokine Res. 30, 777-785
28. Baker, D. P., Lin, E. Y., Lin, K., Pellegrini, M., Petter, R. C., Chen, L. L., Arduini, R. M., Brickelmaier, M., Wen, D., Hess, D. M., Chen, L., Grant, D., Whitty, A., Gill, A., Lindner, D. J., and Pepinsky, R. B. (2006) N-Terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model Bioconjugate Chem 17, 179-188 (Pubitemid 43157600)
29. Gronke, R. S., Jaquez, O., and Kiistala, M. (2010) Challenges of developing a PEGylated interferon beta-1a. ACS National Meeting, San Francisco, CA.
30. Runkel, L., deDios, C., Karpusas, M., Betzenhauser, M., Muldowney, C., Zafari, M., Benjamin, C. D., Miller, S., Hochman, P. S., and Whitty, A. (2000) Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity Biochemistry 39, 2538-51 (Pubitemid 30148906)
31. Karpusas, M., Nolte, M., Benton, C. B., Meier, W., Lipscomb, W. N., and Goelz, S. (1997) The crystal structure of human interferon beta at 2.2-A resolution Proc. Natl. Acad. Sci. U. S. A. 94, 11813-11818
32. Pepinsky, R. B., LePage, D. J., Gill, A., Chakraborty, A., Vaidyanathan, S., Green, M., Baker, D. P., Whalley, E., Hochman, P. S., and Martin, P. (2001) Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity J. Pharmacol. Exp. Ther. 297, 1059-1066 (Pubitemid 32472504)
33. Grabstein, K. H., Wang, A., Nairn, N. W., McCraith, S., and Datta, D. (2009) Modified human interferon-beta polypeptides. US patent 7,632,492, Allozyne.
34. Wang, A., Winblade Nairn, N., Johnson, R. S., Tirrell, D. A., and Grabstein, K. (2008) Processing of N-terminal unnatural amino acids in recombinant human interferon-beta in Escherichia coli ChemBioChem 9, 324-330 (Pubitemid 351196801)
35. Tornoe, C. W., Christensen, C., and Meldal, M. (2002) Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides J. Org. Chem. 67, 3057-3064 (Pubitemid 34457265)
36. Rostovtsev, V. V., Green, L. G., Fokin, V. V., and Sharpless, K. B. (2002) A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes Angew. Chem., Int. Ed. Engl. 41, 2596-2599 (Pubitemid 34803480)
37. Link, A. J. and Tirrell, D. A. (2003) Cell surface labeling of Escherichia coli via copper(I)-catalyzed [3 + 2] cycloaddition J. Am. Chem. Soc. 125, 11164-11165 (Pubitemid 37108030)
38. Wang, Q., Chan, T. R., Hilgraf, R., Fokin, V. V., Sharpless, K. B., and Finn, M. G. (2003) Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition J. Am. Chem. Soc. 125, 3192-3193 (Pubitemid 36512443)
39. Lin, L. S., Yamamoto, R., and Drummond, R. J. (1986) Purification of recombinant human interferon beta expressed in Escherichia coli Methods Enzymol. 119, 183-192 (Pubitemid 16025111)
40. Russell-Harde, D., Knauf, M., and Croze, E. (1995) The use of Zwittergent 3-14 in the purification of recombinant human interferon-beta Ser17 (Betaseron) J. Interferon Cytokine Res. 15, 31-37
41. Stryer, L. (1995) Biochemistry, 4th ed., W. H. Freeman and Company, New York.
42. Dai, S. and Tam, K. C. (2001) Isothermal titration calorimetry studies of binding interactions between polyethylene glycol and ionic surfactants J. Phys. Chem. B 105, 10759-10763 (Pubitemid 35338494)
43. Fee, C. J. and Van Alstine, J. M. (2004) Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins Bioconjugate Chem 15, 1304-1313 (Pubitemid 39552020)
44. Speers, A. E., Adam, G. C., and Cravatt, B. F. (2003) Activity-based protein profiling in vivo using a copper(I)-catalyzed azide-alkyne [3 + 2] cycyloaddition J. Am. Chem. Soc. 125, 4686-4687 (Pubitemid 36505343)
45. Houghton, E. A. and Nicholas, K. M. (2009) In vitro reactive oxygen species production by histatins and copper(I,II) J. Biol. Inorg. Chem. 14, 243-251
46. Presolski, S. I., Hong, V., Cho, S. H., and Finn, M. G. (2010) Tailored ligand acceleration of the Cu-catalyzed azide-alkyne cycloaddition reaction: practical and mechanistic implications J. Am. Chem. Soc. 132, 14570-14576
47. McKenna, S. D., Vergilis, K., Arulanandam, A. R. N., Weiser, W. Y., Nabioullin, R., and Tepper, M. A. (2004) Formation of human IFN-b complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice J. Interferon Cytokine Res. 24, 119-129 (Pubitemid 38253639)
48. Meldal, M. and Tornoe, C. W. (2008) Cu-catalyzed azide-alkyne cycloaddition Chem. Rev. 108, 2952-3015
49. Grabstein, K. H., Wang, A., Nairn, N. W., and Graddis, T. J. (2010) Methods of modifying polypeptides comprising nonnatural amino acids. US patent 7,829,659, Allozyne.
50. Deiters, A., Cropp, T. A., Summerer, D., Mukherji, M., and Schultz, P. G. (2004) Site-specific PEGylation of proteins containing unnatural amino acids Bioorg. Med. Chem. Lett. 14, 5743-5745 (Pubitemid 39421512)
51. Sen Gupta, S., Kuzelka, J., Singh, P., Lewis, W. G., Manchester, M., and Finn, M. G. (2005) Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold Bioconjugate Chem. 16, 1572-1579 (Pubitemid 41681525)
52. Strable, E., Prasuhn, D. E., Jr., Udit, A. K., Brown, S., Link, A. J., Ngo, J. T., Lander, G., Quispe, J., Potter, C. S., Carragher, B., Tirrell, D. A., and Finn, M. G. (2008) Unnatural amino acid incorporation into virus-like particles Bioconjugate Chem. 19, 866-875 (Pubitemid 351614542)
53. Hong, V., Presolski, S. I., Ma, C., and Finn, M. G. (2009) Analysis and optimization of copper-catalyzed azide-alkyne cycloaddition for bioconjugation Angew. Chem., Int. Ed. Engl. 48, 9879-9883
54. Hong, V., Udit, A. K., Evans, R. A., and Finn, M. G. (2008) Electrochemically protected copper(I)-catalyzed azide-alkyne cycloaddition ChemBioChem 9, 1481-1486
55. Grabstein, K., Brady, W., King, G., Nairn, N. W., Shanebeck, K. D., Slagle, P. H., Thornton, K. C., VanBrunt, M. P., Wang, A., and Xu, H. (2012) Novel antibody derivatives. Patent application WO2012032181, Allozyne.
56. Veronese, F. M., Mero, A., Caboi, F., Sergi, M., Marongiu, C., and Pasut, G. (2007) Site-specific pegylation of G-CSF by reversible denaturation Bioconjugate Chem. 18, 1824-1830 (Pubitemid 350219980)
57. Kim, M. Y., Kwon, J. S., Kim, H. J., and Lee, E. K. (2007) In vitro refolding of PEGylated lipase J. Biotechnol. 131, 177-179 (Pubitemid 47187510)
58. Sirokman, G. and Fasman, G. D. (1993) Refolding and proton pumping activity of a polyethylene glycol-bacteriorhodopsin water-soluble conjugate Protein Sci. 2, 1161-1170 (Pubitemid 23191757)
59. Wei, J. and Fasman, G. D. (1995) A poly(ethylene glycol) water-soluble conjugate of porin: refolding to the native state Biochemistry 34, 6408-6415
60. Kubetzko, S., Sarkar, C. A., and Pluckthun, A. (2005) Protein PEGylation decreases observed target association rates via a dual blocking mechanism Mol. Pharmacol. 68, 1439-1454 (Pubitemid 41540000)
61. Mager, D. E., Neuteboom, B., and Jusko, W. J. (2005) Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys Pharm. Res. 22, 58-61 (Pubitemid 40558146)
62. Harris, J. M. and Chess, R. B. (2003) Effect of pegylation on pharmaceuticals Nature Rev. Drug Discovery 2, 214-221 (Pubitemid 37361666)
63. Lide, D. R., Ed. (2005) CRC Handbook of Chemistry and Physics, 86th ed., Taylor & Francis, Boca Raton, FL.